ARGX (ARGX) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving ARGX (ARGX) right now is Vyvgart franchise momentum: Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. Revenue (2025 product net sales) is ~$4.15B. If that keeps playing out, the setup is favourable; the risk to it is argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. No one can predict where ARGX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive ARGX (ARGX) higher?
1. Vyvgart franchise momentum
Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. Uptake of the subcutaneous Hytrulo formulation and continued gMG and CIDP adoption are the core revenue engine. Each new label and geography adds to a still-expanding addressable base.
2. Label and indication expansion
argenx is pursuing efgartigimod in seronegative gMG, ocular myasthenia gravis, primary ITP, Graves' disease, myositis, and Sjogren's disease. A widening set of approved uses could turn a single molecule into a multi-indication franchise. Regulatory decisions and Phase 3 readouts across 2026 are the near-term swing factors.
3. Deep autoimmune pipeline
Beyond efgartigimod, argenx is advancing next-generation FcRn candidates (such as ARGX-213 and ARGX-124) and first-in-class assets including empasiprubart (a C2 complement inhibitor) and adimanebart. Its Vision 2030 framework targets 10 labeled indications and five pipeline candidates in Phase 3. This breadth is what supports the long-duration growth narrative.
4. Profitability and balance sheet
argenx has crossed into sustained profitability, reporting Q1 2026 profit of about $366 million (up 116% year over year) and adjusted EPS of $5.52. It held roughly $4.9 billion in cash and current financial assets at quarter end. That cushion funds pipeline investment without near-term dependence on capital markets.
What could weigh on ARGX?
argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The FcRn field is crowding: UCB (rozanolixizumab, zilucoplan), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are all competing in overlapping indications, and AstraZeneca's complement inhibitors address parts of the same market. Pipeline setbacks or missed Phase 3 readouts could sharply reset expectations given the high valuation. As an ADR of a European company, holders also carry currency and cross-listing considerations. Biotech shares like ARGX tend to be volatile around clinical and regulatory events.
Where ARGX trades today
A forecast starts from where the stock actually is. These are ARGX's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ARGX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ARGX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ARGX guide and whether ARGX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ARGX outlook
The bottom line: what is driving ARGX (ARGX) is Vyvgart franchise momentum, with revenue (2025 product net sales) at ~$4.15B. If that keeps playing out the setup is favourable; the risk is argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. No one can predict the price, so treat any ARGX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ARGX with Walnut
Use ARGX as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for ARGX (ARGX)?
+
No one can reliably predict where ARGX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push ARGX higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ARGX higher?
+
The main growth drivers are Vyvgart franchise momentum; Label and indication expansion; Deep autoimmune pipeline. Whether they play out is the real question, not a guaranteed path.
What are the risks to ARGX?
+
argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The FcRn field is crowding: UCB (rozanolixizumab, zilucoplan), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are all competing in overlapping indications, and AstraZeneca's complement inhibitors address parts of the same market. Pipeline setbacks or missed Phase 3 readouts could sharply reset expectations given the high valuation. As an ADR of a European company, holders also carry currency and cross-listing considerations. Biotech shares like ARGX tend to be volatile around clinical and regulatory events.
Will ARGX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. ARGX's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ARGX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ARGX "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is argenx growing?
+
Growth has been rapid. Global product net sales rose about 90% year over year in 2025 to roughly $4.15 billion, and Q1 2026 sales of about $1.3 billion were up 63% from a year earlier, marking the 17th consecutive quarter of Vyvgart growth.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.